UK markets closed

Dynavax Technologies Corporation (0IDA.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
11.35+0.29 (+2.58%)
At close: 04:59PM BST
Full screen
Previous close11.06
Open11.30
Bid0.00 x N/A
Ask0.00 x N/A
Day's range11.26 - 11.44
52-week range9.50 - 15.15
Volume119
Avg. volume1,118
Market cap240.43M
Beta (5Y monthly)1.28
PE ratio (TTM)0.15
EPS (TTM)0.75
Earnings date06 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

    Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close.

  • PR Newswire

    Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program

    Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company's investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus.

  • PR Newswire

    Dynavax to Present at Upcoming Investor Conferences

    Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: